The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.

  • 1

    JabbourEJFaderlSKantarjianHM. Adult acute lymphoblastic leukemia. Mayo Clin Proc2005;80:15171527.

  • 2

    National Cancer Institute. SEER Stat Fact Sheet: Acute Lymphocytic Leukemia. Bethesda, MD: 2011. Available at: http://seer.cancer.gov/statfacts/html/alyl.html. Accessed March 2012.

    • Search Google Scholar
    • Export Citation
  • 3

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 4

    EsparzaSDSakamotoKM. Topics in pediatric leukemia--acute lymphoblastic leukemia. MedGenMed2005;7:23.

  • 5

    GaynonPSAngiolilloALCarrollWL. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group report. Leukemia2010;24:285297.

    • Search Google Scholar
    • Export Citation
  • 6

    PuiCHEvansWE. Acute lymphoblastic leukemia. N Engl J Med1998;339:605615.

  • 7

    PuiCHPeiDSandlundJT. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia2010;24:371382.

    • Search Google Scholar
    • Export Citation
  • 8

    AnninoLVegnaMLCameraA. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood2002;99:863871.

    • Search Google Scholar
    • Export Citation
  • 9

    BassanRHoelzerD. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol2011;29:532543.

  • 10

    KantarjianHThomasDO’BrienS. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer2004;101:27882801.

    • Search Google Scholar
    • Export Citation
  • 11

    LarsonRADodgeRKBurnsCP. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood1995;85:20252037.

    • Search Google Scholar
    • Export Citation
  • 12

    LinkerCDamonLRiesCNavarroW. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol2002;20:24642471.

    • Search Google Scholar
    • Export Citation
  • 13

    RoweJMBuckGBurnettAK. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood2005;106:37603767.

    • Search Google Scholar
    • Export Citation
  • 14

    TakeuchiJKyoTNaitoK. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia2002;16:12591266.

    • Search Google Scholar
    • Export Citation
  • 15

    ThomasXBoironJMHuguetF. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol2004;22:40754086.

    • Search Google Scholar
    • Export Citation
  • 16

    PuiCHRellingMVDowningJR. Acute lymphoblastic leukemia. N Engl J Med2004;350:15351548.

  • 17

    StockW. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program2010;2010:2129.

  • 18

    FaderlSO’BrienSPuiCH. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer2010;116:11651176.

  • 19

    BorowitzMJChanJKC. B lymphoblastic leukaemia/lymphoma, not otherwise specified. In: SwerdlowSHCampoEHarrisNL. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC; 2008:168170.

    • Search Google Scholar
    • Export Citation
  • 20

    BorowitzMJChanJKC. T lymphoblastic leukaemia/lymphoma. In: SwerdlowSHCampoEHarrisNL. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC; 2008176178.

    • Search Google Scholar
    • Export Citation
  • 21

    BorowitzMJChanJKC. B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: SwerdlowSHCampoEHarrisNL. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC; 2008:171175.

    • Search Google Scholar
    • Export Citation
  • 22

    BassanRGattaGTondiniCWillemzeR. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol2004;50:223261.

  • 23

    GokbugetNHoelzerD. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program2006:133141.

  • 24

    ThomasDAO’BrienSJorgensenJL. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood2009;113:63306337.

    • Search Google Scholar
    • Export Citation
  • 25

    Coustan-SmithEMullighanCGOnciuM. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol2009;10:147156.

    • Search Google Scholar
    • Export Citation
  • 26

    ArmstrongSALookAT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol2005;23:63066315.

  • 27

    SeibelNL. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program2008:374380.

    • Search Google Scholar
    • Export Citation
  • 28

    BurmeisterTSchwartzSBartramCR. Patients’ age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood2008;112:918919.

    • Search Google Scholar
    • Export Citation
  • 29

    GleissnerBGokbugetNBartramCR. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood2002;99:15361543.

    • Search Google Scholar
    • Export Citation
  • 30

    PuiCHEvansWE. Treatment of acute lymphoblastic leukemia. N Engl J Med2006;354:166178.

  • 31

    AricoMValsecchiMGCamittaB. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med2000;342:9981006.

    • Search Google Scholar
    • Export Citation
  • 32

    SchultzKRPullenDJSatherHN. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood2007;109:926935.

    • Search Google Scholar
    • Export Citation
  • 33

    SmithMArthurDCamittaB. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol1996;14:1824.

    • Search Google Scholar
    • Export Citation
  • 34

    NachmanJ. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol2005;130:166173.

    • Search Google Scholar
    • Export Citation
  • 35

    HoelzerDThielELofflerH. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood1984;64:3847.

    • Search Google Scholar
    • Export Citation
  • 36

    HoelzerDThielELofflerH. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood1988;71:123131.

    • Search Google Scholar
    • Export Citation
  • 37

    MoormanAVHarrisonCJBuckGAN. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood2007;109:31893197.

    • Search Google Scholar
    • Export Citation
  • 38

    PullarkatVSlovakMLKopeckyKJ. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood2008;111:25632572.

    • Search Google Scholar
    • Export Citation
  • 39

    KampsWABokkerinkJPHakvoort-CammelFG. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996). Leukemia2002;16:10991111.

    • Search Google Scholar
    • Export Citation
  • 40

    MorickeAReiterAZimmermannM. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95Blood2008;111:44774489.

    • Search Google Scholar
    • Export Citation
  • 41

    SchrappeMReiterALudwigWD. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood2000;95:33103322.

    • Search Google Scholar
    • Export Citation
  • 42

    SeibelNLSteinherzPGSatherHN. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood2008;111:25482555.

    • Search Google Scholar
    • Export Citation
  • 43

    StockWLaMSanfordB. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood2008;112:16461654.

    • Search Google Scholar
    • Export Citation
  • 44

    BostromBCSenselMRSatherHN. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood2003;101:38093817.

    • Search Google Scholar
    • Export Citation
  • 45

    MitchellCDRichardsSMKinseySE. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol2005;129:734745.

    • Search Google Scholar
    • Export Citation
  • 46

    PuiCH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program2006:142146.

    • Search Google Scholar
    • Export Citation
  • 47

    TeuffelOKusterSPHungerSP. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia2011:12321238.

    • Search Google Scholar
    • Export Citation
  • 48

    KantarjianHMO’BrienSSmithTL. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol2000;18:547561.

    • Search Google Scholar
    • Export Citation
  • 49

    KollerCAKantarjianHMThomasD. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia1997;11:20392044.

    • Search Google Scholar
    • Export Citation
  • 50

    HoelzerDLudwigWDThielE. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood1996;87:495508.

  • 51

    de LabartheARousselotPHuguet-RigalF. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood2007;109:14081413.

    • Search Google Scholar
    • Export Citation
  • 52

    OttmannODombretHMartinelliG. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood2007;110:23092315.

    • Search Google Scholar
    • Export Citation
  • 53

    OttmannOGWassmannBPfeiferH. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer2007;109:20682076.

    • Search Google Scholar
    • Export Citation
  • 54

    RavandiFO’BrienSThomasD. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood2010;116:20702077.

    • Search Google Scholar
    • Export Citation
  • 55

    SchultzKRBowmanWPAledoA. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol2009;27:51755181.

    • Search Google Scholar
    • Export Citation
  • 56

    ThomasDAFaderlSCortesJ. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood2004;103:43964407.

    • Search Google Scholar
    • Export Citation
  • 57

    WassmannBPfeiferHGoekbugetN. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood2006;108:14691477.

    • Search Google Scholar
    • Export Citation
  • 58

    YanadaMTakeuchiJSugiuraI. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol2006;24:460466.

    • Search Google Scholar
    • Export Citation
  • 59

    ThomasDAFaderlSO’BrienS. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer2006;106:15691580.

    • Search Google Scholar
    • Export Citation
  • 60

    ThomasDAO’BrienSFaderlS. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol2010;28:38803889.

    • Search Google Scholar
    • Export Citation
  • 61

    BergSLBlaneySMDevidasM. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol2005;23:33763382.

    • Search Google Scholar
    • Export Citation
  • 62

    CohenMHJohnsonJRJusticeRPazdurR. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist2008;13:709714.

    • Search Google Scholar
    • Export Citation
  • 63

    DeAngeloDJYuDJohnsonJL. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood2007;109:51365142.

    • Search Google Scholar
    • Export Citation
  • 64

    AricoMSchrappeMHungerSP. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol2010;28:47554761.

    • Search Google Scholar
    • Export Citation
  • 65

    OttmannOGDrukerBJSawyersCL. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood2002;100:19651971.

    • Search Google Scholar
    • Export Citation
  • 66

    WassmannBGokbugetNScheuringUJ. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol2003;82:716720.

    • Search Google Scholar
    • Export Citation
  • 67

    TowatariMYanadaMUsuiN. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood2004;104:35073512.

    • Search Google Scholar
    • Export Citation
  • 68

    Tanguy-SchmidtAde LabartheARousselotP. Long-term results of the imatinib GRAAPH-2003 Study in newly-diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia [abstract]. Blood2009;114:Abstract 3080.

    • Search Google Scholar
    • Export Citation
  • 69

    ThomasDAO’BrienSMFaderlS. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol2010;28:Abstract 6506.

    • Search Google Scholar
    • Export Citation
  • 70

    BurkeMJCaoQTrotzB. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer2009;53:12891294.

    • Search Google Scholar
    • Export Citation
  • 71

    RivesSEstellaJGomezP. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol2011;154:600611.

    • Search Google Scholar
    • Export Citation
  • 72

    CornelissenJJCarstonMKollmanC. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood2001;97:15721577.

    • Search Google Scholar
    • Export Citation
  • 73

    EsperouHBoironJMCayuelaJM. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant2003;31:909918.

    • Search Google Scholar
    • Export Citation
  • 74

    MizutaSMatsuoKYagasakiF. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia2011;25:4147.

    • Search Google Scholar
    • Export Citation
  • 75

    FieldingAKRoweJMRichardsSM. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood2009;113:44894496.

    • Search Google Scholar
    • Export Citation
  • 76

    BassanRRossiGPoglianiEM. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol2010;28:36443652.

    • Search Google Scholar
    • Export Citation
  • 77

    RiberaJMOriolAGonzalezM. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica2010;95:8795.

    • Search Google Scholar
    • Export Citation
  • 78

    ChalandonYThomasXHayetteS. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia [abstract]. Blood2008;112:Abstract 12.

    • Search Google Scholar
    • Export Citation
  • 79

    BranfordSRudzkiZWalshS. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood2002;99:34723475.

    • Search Google Scholar
    • Export Citation
  • 80

    HofmannWKJonesLCLempNA. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood2002;99:18601862.

    • Search Google Scholar
    • Export Citation
  • 81

    JonesDThomasDYinCC. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer2008;113:985994.

    • Search Google Scholar
    • Export Citation
  • 82

    SoveriniSColarossiSGnaniA. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res2006;12:73747379.

    • Search Google Scholar
    • Export Citation
  • 83

    BujassoumSRifkindJLiptonJH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma2004;45:401403.

    • Search Google Scholar
    • Export Citation
  • 84

    LeisJFStepanDECurtinPT. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma2004;45:695698.

    • Search Google Scholar
    • Export Citation
  • 85

    PfeiferHWassmannBHofmannWK. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res2003;9:46744681.

    • Search Google Scholar
    • Export Citation
  • 86

    TakayamaNSatoNO’BrienSG. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol2002;119:106108.

    • Search Google Scholar
    • Export Citation
  • 87

    O’HareTWaltersDKStoffregenEP. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res2005;65:45004505.

    • Search Google Scholar
    • Export Citation
  • 88

    ShahNPTranCLeeFY. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science2004;305:399401.

  • 89

    TalpazMShahNPKantarjianH. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med2006;354:25312541.

    • Search Google Scholar
    • Export Citation
  • 90

    LillyMBOttmannOGShahNP. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol2010;85:164170.

    • Search Google Scholar
    • Export Citation
  • 91

    PorkkaKKoskenvesaPLundanT. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood2008;112:10051012.

    • Search Google Scholar
    • Export Citation
  • 92

    FoaRVitaleAGuariniA. Dasatinib monotherapy effective and feasible as firstline treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study [abstract]. Blood2008;112(Suppl 11):Abstract 305.

    • Search Google Scholar
    • Export Citation
  • 93

    FoaRVitaleAVignettiM. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood2011;118:65216528.

    • Search Google Scholar
    • Export Citation
  • 94

    DelannoyADelabesseELheritierV. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia2006;20:15261532.

    • Search Google Scholar
    • Export Citation
  • 95

    VignettiMFaziPCiminoG. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood2007;109:36763678.

    • Search Google Scholar
    • Export Citation
  • 96

    FieldingAKRichardsSMChopraR. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood2007;109:944950.

    • Search Google Scholar
    • Export Citation
  • 97

    OriolAVivesSHernandez-RivasJM. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica2010;95:589596.

    • Search Google Scholar
    • Export Citation
  • 98

    TavernierEBoironJMHuguetF. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia2007;21:19071914.

    • Search Google Scholar
    • Export Citation
  • 99

    ThomasDAKantarjianHSmithTL. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer1999;86:12161230.

    • Search Google Scholar
    • Export Citation
  • 100

    HuYLiuYPelletierS. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet2004;36:453461.

    • Search Google Scholar
    • Export Citation
  • 101

    HofmannWKKomorMWassmannB. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood2003;102:659661.

    • Search Google Scholar
    • Export Citation
  • 102

    PfeiferHWassmannBPavlovaA. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood2007;110:727734.

    • Search Google Scholar
    • Export Citation
  • 103

    RedaelliSPiazzaRRostagnoR. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol2009;27:469471.

    • Search Google Scholar
    • Export Citation
  • 104

    VerstovsekSGolemovicMKantarjianH. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer2005;104:12301236.

    • Search Google Scholar
    • Export Citation
  • 105

    KantarjianHGilesFWunderleL. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med2006;354:25422551.

    • Search Google Scholar
    • Export Citation
  • 106

    OttmannOGLarsonRAKantarjianHM. Nilotinib in patients (pts) with relapsed/refractory Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib [abstract]. Blood2007;110:Abstract 2815.

    • Search Google Scholar
    • Export Citation
  • 107

    MullerMCCortesJEKimDW. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood2009;114:49444953.

    • Search Google Scholar
    • Export Citation
  • 108

    SoveriniSColarossiSGnaniA. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica2007;92:401404.

    • Search Google Scholar
    • Export Citation
  • 109

    SoveriniSMartinelliGColarossiS. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol2006;24:e5152.

    • Search Google Scholar
    • Export Citation
  • 110

    SoveriniSHochhausANicoliniFE. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood2011;118:12081215.

    • Search Google Scholar
    • Export Citation
  • 111

    CortesJEKim D-WPinilla-IbarzJ. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract]. Blood2011;118:Abstract 109.

    • Search Google Scholar
    • Export Citation
  • 112

    KhouryHJCortesJEGambacorti-PasseriniC. Activity of bosutinib by baseline and emergent mutation status in Philadelphia chromosome-positive leukemia patients with resistance or intolerance to other tyrosine kinase inhibitors [abstract]. Blood2011;118:Abstract 110.

    • Search Google Scholar
    • Export Citation
  • 113

    KhouryHJCortesJEKantarjianHM. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood2012;119:34033412.

    • Search Google Scholar
    • Export Citation
  • 114

    IshidaYTerasakoKOshimaK. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Int J Hematol2010;92:542546.

    • Search Google Scholar
    • Export Citation
  • 115

    MillotFCividinMBrizardF. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Pediatr Blood Cancer2009;52:891892.

    • Search Google Scholar
    • Export Citation
  • 116

    CollinsRHJrGoldsteinSGiraltS. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant2000;26:511516.

  • 117

    KolbHJSchattenbergAGoldmanJM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood1995;86:20412050.

    • Search Google Scholar
    • Export Citation
  • 118

    KeilFKalhsPHaasOA. Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes. Br J Haematol1997;97:161164.

    • Search Google Scholar
    • Export Citation
  • 119

    MatsueKTabayashiTYamadaKTakeuchiM. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant2002;29:6366.

    • Search Google Scholar
    • Export Citation
  • 120

    YazakiMAndohMItoT. Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion. Bone Marrow Transplant1997;19:393394.

    • Search Google Scholar
    • Export Citation
  • 121

    TiribelliMSperottoACandoniA. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res2009;33:174177.

    • Search Google Scholar
    • Export Citation
  • 122

    YoshimitsuMFujiwaraHOzakiA. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol2008;88:331335.

    • Search Google Scholar
    • Export Citation
  • 123

    RellingMVHancockMLRiveraGK. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst1999;91:20012008.

    • Search Google Scholar
    • Export Citation
  • 124

    BoisselNAuclercMFLheritierV. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol2003;21:774780.

    • Search Google Scholar
    • Export Citation
  • 125

    de BontJMHoltBvdDekkerAW. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia2004;18:20322035.

    • Search Google Scholar
    • Export Citation
  • 126

    HallbookHGustafssonGSmedmyrB. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer2006;107:15511561.

    • Search Google Scholar
    • Export Citation
  • 127

    RamanujacharRRichardsSHannI. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer2007;48:254261.

    • Search Google Scholar
    • Export Citation
  • 128

    BarryEDeAngeloDJNeubergD. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol2007;25:813819.

    • Search Google Scholar
    • Export Citation
  • 129

    NachmanJBLaMKHungerSP. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. J Clin Oncol2009;27:51895194.

    • Search Google Scholar
    • Export Citation
  • 130

    PuiCHCampanaDPeiD. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med2009;360:27302741.

  • 131

    PuiCHPeiDCampanaD. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol2011;29:386391.

  • 132

    RiberaJMOriolASanzMA. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol2008;26:18431849.

    • Search Google Scholar
    • Export Citation
  • 133

    DeAngeloDJDahlbergSSilvermanLB. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia [abstract]. Blood2007;110:Abstract 587.

    • Search Google Scholar
    • Export Citation
  • 134

    HuguetFLeguayTRaffouxE. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol2009;27:911918.

    • Search Google Scholar
    • Export Citation
  • 135

    GlaxoSmithKline. Prescribing Information. ARRANON (nelarabine) Injection. 2009. Available at: http://us.gsk.com/products/assets/us_arranon.pdf. Accessed June 2011.

    • Search Google Scholar
    • Export Citation
  • 136

    WinterSSDevidasMWoodB. Nelarabine may be safely incorporated into a phase III study for newly diagnosed T-lineage acute lymphoblastic leukemia: a report from the Children’s Oncology Group [abstract]. Blood2010;116:Abstract 865.

    • Search Google Scholar
    • Export Citation
  • 137

    RiberaJMOriolABethencourtC. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica2005;90:13461356.

    • Search Google Scholar
    • Export Citation
  • 138

    GoldstoneAHRichardsSMLazarusHM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood2008;111:18271833.

    • Search Google Scholar
    • Export Citation
  • 139

    CornelissenJJvan der HoltBVerhoefGE. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood2009;113:13751382.

    • Search Google Scholar
    • Export Citation
  • 140

    RamRGafter-GviliAVidalL. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer2010;116:34473457.

    • Search Google Scholar
    • Export Citation
  • 141

    YanadaMMatsuoKSuzukiTNaoeT. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer2006;106:26572663.

    • Search Google Scholar
    • Export Citation
  • 142

    MarksDIPaiettaEMMoormanAV. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood2009;114:51365145.

    • Search Google Scholar
    • Export Citation
  • 143

    MaurySHuguetFLeguayT. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica2010;95:324328.

    • Search Google Scholar
    • Export Citation
  • 144

    NguyenKDevidasMChengSC. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia2008;22:21422150.

    • Search Google Scholar
    • Export Citation
  • 145

    EinsiedelHGvon StackelbergAHartmannR. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol2005;23:79427950.

    • Search Google Scholar
    • Export Citation
  • 146

    TallenGRateiRMannG. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol2010;28:23392347.

    • Search Google Scholar
    • Export Citation
  • 147

    MalempatiSGaynonPSSatherH. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952. J Clin Oncol2007;25:58005807.

    • Search Google Scholar
    • Export Citation
  • 148

    Genzyme Corporation Prescribing Information. Clolar (clofarabine) Injection for Intravenous Use. 2010. Available at: http://www.clolar.com/~/media/Files/Clolar/prescribing-information.pdf. Accessed January 2012.

    • Search Google Scholar
    • Export Citation
  • 149

    JehaSGaynonPSRazzoukBI. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol2006;24:19171923.

    • Search Google Scholar
    • Export Citation
  • 150

    LocatelliFTestiAMBernardoME. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol2009;147:371378.

    • Search Google Scholar
    • Export Citation
  • 151

    PigneuxASauvezieMVeyN. Clofarabine combinations in adults with refractory/relapsed acute lymphoblastic leukemia (ALL): a GRAALL report [abstract]. Blood2011;118:Abstract 2586.

    • Search Google Scholar
    • Export Citation
  • 152

    SchillerGLeeMTerritoM. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. Am J Hematol1993;43:195199.

    • Search Google Scholar
    • Export Citation
  • 153

    WeissMAAliffTBTallmanMS. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer2002;95:581587.

    • Search Google Scholar
    • Export Citation
  • 154

    FaderlSThomasDAO’BrienS. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk2011;11:5459.

    • Search Google Scholar
    • Export Citation
  • 155

    KantarjianHThomasDJorgensenJ. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol2012;13:403411.

    • Search Google Scholar
    • Export Citation
  • 156

    O’BrienSThomasDAOhanianM. Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, is active in refractory-relapse acute lymphocytic leukemia (R-R ALL) [abstract]. Blood2011;118:Abstract 875.

    • Search Google Scholar
    • Export Citation
  • 157

    ToppMSGoekbugetNZugmaierG. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial [abstract]. Blood2011;118:Abstract 252.

    • Search Google Scholar
    • Export Citation
  • 158

    ToppMSKuferPGokbugetN. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol2011;29:24932498.

    • Search Google Scholar
    • Export Citation
  • 159

    HahnTWallDCamittaB. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant2006;12:130.

    • Search Google Scholar
    • Export Citation
  • 160

    EapenMRaetzEZhangMJ. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood2006;107:49614967.

    • Search Google Scholar
    • Export Citation
  • 161

    BurgerBZimmermannMMannG. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol2003;21:184188.

    • Search Google Scholar
    • Export Citation
  • 162

    LazarusHMRichardsSMChopraR. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood2006;108:465472.

    • Search Google Scholar
    • Export Citation
  • 163

    RemanOPigneuxAHuguetF. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res2008;32:17411750.

    • Search Google Scholar
    • Export Citation
  • 164

    SanchoJMRiberaJMOriolA. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer2006;106:25402546.

    • Search Google Scholar
    • Export Citation
  • 165

    Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood Adolescent and Young Adult Cancers. 2008. Available at: http://www.survivorshipguidelines.org/. Accessed January 2012.

    • Search Google Scholar
    • Export Citation
  • 166

    MortuzaFYPapaioannouMMoreiraIM. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol2002;20:10941104.

    • Search Google Scholar
    • Export Citation
  • 167

    NealeGACoustan-SmithEStowP. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia2004;18:934938.

    • Search Google Scholar
    • Export Citation
  • 168

    KerstGKreyenbergHRothC. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol2005;128:774782.

    • Search Google Scholar
    • Export Citation
  • 169

    Coustan-SmithESanchoJBehmFG. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood2002;100:5258.

    • Search Google Scholar
    • Export Citation
  • 170

    Coustan-SmithESanchoJHancockML. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood2000;96:26912696.

    • Search Google Scholar
    • Export Citation
  • 171

    CaveHvan der Werff ten BoschJSuciuS. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med1998;339:591598.

    • Search Google Scholar
    • Export Citation
  • 172

    Coustan-SmithEBehmFGSanchezJ. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet1998;351:550554.

    • Search Google Scholar
    • Export Citation
  • 173

    StowPKeyLChenX. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood2010;115:46574663.

    • Search Google Scholar
    • Export Citation
  • 174

    ConterVBartramCRValsecchiMG. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood2010;115:32063214.

    • Search Google Scholar
    • Export Citation
  • 175

    BassoGVeltroniMValsecchiMG. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol2009;27:51685174.

    • Search Google Scholar
    • Export Citation
  • 176

    Panzer-GrumayerERSchneiderMPanzerS. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood2000;95:790794.

    • Search Google Scholar
    • Export Citation
  • 177

    KoRHJiLBarnetteP. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol2010;28:648654.

    • Search Google Scholar
    • Export Citation
  • 178

    Coustan-SmithEGajjarAHijiyaN. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia2004;18:499504.

    • Search Google Scholar
    • Export Citation
  • 179

    PaganinMZeccaMFabbriG. Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia. Leukemia2008;22:21932200.

    • Search Google Scholar
    • Export Citation
  • 180

    BruggemannMRaffTFlohrT. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood2006;107:11161123.

    • Search Google Scholar
    • Export Citation
  • 181

    HolowieckiJKrawczyk-KulisMGiebelS. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol2008;142:227237.

    • Search Google Scholar
    • Export Citation
  • 182

    PatelBRaiLBuckG. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol2010;148:8089.

    • Search Google Scholar
    • Export Citation
  • 183

    VidrialesMBPerezJJLopez-BergesMC. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood2003;101:46954700.

    • Search Google Scholar
    • Export Citation
  • 184

    BassanRSpinelliOOldaniE. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood2009;113:41534162.

    • Search Google Scholar
    • Export Citation
  • 185

    RaffTGokbugetNLuschenS. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood2007;109:910915.

    • Search Google Scholar
    • Export Citation
  • 186

    DworzakMNFroschlGPrintzD. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood2002;99:19521958.

    • Search Google Scholar
    • Export Citation
  • 187

    BruggemannMSchrauderARaffT. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia2010;24:521535.

    • Search Google Scholar
    • Export Citation
  • 188

    CampanaD. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program2010;2010:712.

  • 189

    GoodmanJLWinstonDJGreenfieldRA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 190

    MarrKASeidelKSlavinMA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood2000;96:20552061.

    • Search Google Scholar
    • Export Citation
  • 191

    SlavinMAOsborneBAdamsR. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 192

    HughesWTRiveraGKSchellMJ. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med1987;316:16271632.

    • Search Google Scholar
    • Export Citation
  • 193

    LindemulderSAlbanoE. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics2007;120:e4751.

    • Search Google Scholar
    • Export Citation
  • 194

    MattanoLAJrSatherHNTriggMENachmanJB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol2000;18:32623272.

    • Search Google Scholar
    • Export Citation
  • 195

    te WinkelMLPietersRHopWC. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol2011;29:41434150.

    • Search Google Scholar
    • Export Citation
  • 196

    VoraA. Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol2011;155:549560.

  • 197

    AsselinBL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol1999;457:621629.

    • Search Google Scholar
    • Export Citation
  • 198

    PietersRHungerSPBoosJ. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer2011;117:238249.

    • Search Google Scholar
    • Export Citation
  • 199

    StockWDouerDDeangeloDJ. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma2011;52:22372253.

    • Search Google Scholar
    • Export Citation
  • 200

    AvramisVISencerSPericlouAP. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood2002;99:19861994.

    • Search Google Scholar
    • Export Citation
  • 201

    WangBRellingMVStormMC. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia2003;17:15831588.

    • Search Google Scholar
    • Export Citation
  • 202

    Zalewska-SzewczykBGachAWykaK. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med2009;9:113116.

    • Search Google Scholar
    • Export Citation
  • 203

    WillerAGerssJKonigT. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood2011;118:57745782.

    • Search Google Scholar
    • Export Citation
  • 204

    VroomanLMSupkoJGNeubergDS. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer2010;54:199205.

    • Search Google Scholar
    • Export Citation
  • 205

    EUSA Pharma (USA) Inc. Prescribing Information. Asparaginase Erwinia chrysanthemi ERWINAZE™ For Injection Intramuscular Use. 2011. Available at: http://www.erwinaze.com/pdf/PI_18-Nov2011.pdf. Accessed February 2012.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 192 192 15
PDF Downloads 49 49 2
EPUB Downloads 0 0 0